Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF RN564 IN WOMEN WITH OSTEOPENIA AND IN HEALTHY MEN

NCT01293487 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01293487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01293487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF RN564 IN WOMEN WITH OSTEOPENIA AND IN HEALTHY MEN
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2011
Completion date
May 24, 2012
Enrollment
68 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bone disease, osteopenia, osteoporosis